• Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World
Newsy Today
news of today
Home - Bone
Tag:

Bone

Health

New Engineered Scaffold Restores Skull Growth in Craniosynostosis Models

by Chief Editor July 5, 2026
written by Chief Editor

Researchers have developed a triphasic biomaterial scaffold that successfully restores the cranial suture stem cell niche in cases of craniosynostosis. According to a study published in Bone Research on May 28, 2026, the scaffold—engineered from poly(L-lactic acid)—prevents premature skull bone fusion by maintaining essential skeletal stem cells, offering a potential alternative to invasive surgical procedures for children affected by the condition.

How Does the Triphasic Scaffold Work?

The scaffold functions by mimicking the natural “bone-suture-bone” architecture of the skull. Led by Yuji Mishina of the University of Michigan and W. Benton Swanson of Harvard University, the team designed the device with three distinct, interconnected compartments. Each compartment features varying pore sizes to control cell behavior.

The central compartment utilizes small pores specifically to preserve the properties of skeletal stem cells. Meanwhile, the larger pores in the surrounding compartments are engineered to promote vascularization and new bone formation. According to the study, this spatial organization allows the scaffold to act as a reservoir for stem cells while simultaneously encouraging the growth of necessary surrounding tissue.

Did you know?

Craniosynostosis affects approximately one in every 2,500 births. It occurs when the fibrous joints between skull bones fuse prematurely, often requiring multiple surgeries to correct the resulting head shape and intracranial pressure.

Can the Scaffold Withstand Biological Pressure?

A primary challenge in treating craniosynostosis is the body’s tendency to trigger abnormal bone growth, or ossification, even after surgical intervention. To test the durability of their design, researchers exposed the scaffold to excessive bone morphogenetic protein activity, which is a common biological driver of suture fusion.

The study found that the central compartment of the scaffold successfully resisted this pressure. By maintaining a non-bony microenvironment, the device prevented the stem cells from prematurely turning into bone. This suggests the scaffold can effectively counteract the biological signals that usually cause post-surgical re-fusion.

Future Trends in Craniofacial Regeneration

The success of the triphasic scaffold in mouse models of midline craniosynostosis points toward a shift in how researchers might approach pediatric skull defects. Current standard treatments rely on mechanical reopening of the skull, which carries a risk of the sutures fusing again. By contrast, the regenerative approach seeks to rebuild the biological niche itself.

According to W. Benton Swanson, the principles of rational biomaterial design demonstrated in this research may eventually extend beyond craniosynostosis. The ability to control stem cell fate through structural engineering provides a framework that could be applied to other skeletal disorders and developmental conditions where tissue loss or abnormal fusion is a factor.

Frequently Asked Questions

What is the main advantage of this new scaffold?

Unlike traditional surgery that simply reshapes the skull, this scaffold regenerates the biological stem cell niche, which helps maintain normal growth patterns and prevents the sutures from fusing again.

What material is the scaffold made of?

The scaffold is made from poly(L-lactic acid), a biodegradable, FDA-approved biomaterial already used in various medical applications.

Has this been tested in humans?

No. As of the May 2026 report in Bone Research, the findings are based on successful experiments in mouse models that closely resemble human nonsyndromic craniosynostosis.

Explore More

Are you interested in the latest developments in regenerative medicine? Subscribe to our monthly research newsletter to stay updated on breakthrough biomaterial studies and pediatric health innovations.

July 5, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Electroacupuncture at Lianquan Point for Post-Stroke Dysphagia Recovery

by Chief Editor June 23, 2026
written by Chief Editor

Researchers at Guangzhou University of Chinese Medicine have identified the hypoglossal nucleus (12N) as the primary brainstem motor node responsible for the swallowing improvements observed after electroacupuncture at the “Lianquan” (CV23) acupoint. Published in Acupuncture Research on August 25, 2025 (DOI: 10.13702/j.1000-0607.20250444), the study confirms that this neural pathway is essential for restoring swallowing function in post-stroke dysphagia (PSD) patients.

How Does Electroacupuncture Affect Swallowing?

Electroacupuncture at the “Lianquan” (CV23) point works by directly engaging brainstem motor circuits rather than acting solely as a local muscle stimulant. According to the study, the hypoglossal nucleus (12N) sends monosynaptic projections—direct neural links—to the tissues surrounding the CV23 acupoint. When researchers applied a 15-minute, 2 Hz, 1 mA stimulation to stroke-affected mice, they observed an immediate increase in swallowing-related muscle electrical activity, verified through electromyography (EMG) and laryngoscopy.

How Does Electroacupuncture Affect Swallowing?
Did you know?

The “Lianquan” (CV23) acupoint is located on the anterior midline of the neck, situated directly above the hyoid bone, a region anatomically positioned to influence tongue movement and the mechanics of swallowing.

Why is the Hypoglossal Nucleus Critical?

The hypoglossal nucleus (12N) serves as a vital “output gate” for swallowing commands. By using chemogenetic inhibition to silence the 12N in research models, the study team demonstrated that the benefits of electroacupuncture were significantly attenuated. In stroke-afflicted mice, silencing this node caused vocal cord movement to slow and muscle activity to revert to impaired levels. This confirms that 12N is not just involved in the process, but is a necessary component for the therapy to function.

What Are the Next Steps for Stroke Rehabilitation?

This research provides a mechanistic foundation for integrating electroacupuncture into standard post-stroke care. The study authors suggest that the hypoglossal nucleus (12N) could become a target for future neuromodulation therapies. While hypoglossal nerve stimulation is currently an established clinical treatment for obstructive sleep apnea, its application for dysphagia remains a new frontier. Future research will likely focus on how upstream brain regions—specifically the nucleus tractus solitarii (NTS) and the intermediate reticular nucleus (IRt)—send signals down to the 12N to initiate the swallowing reflex.

Guangzhou University of Chinese Medicine

Comparison: Current vs. Emerging Swallowing Therapies

Therapy Type Primary Mechanism Current Clinical Status
Electroacupuncture (CV23) Brainstem motor node (12N) activation Rehabilitation/Research
Hypoglossal Nerve Stimulation Direct nerve electrical pacing Standard for Sleep Apnea
Pro Tip:

If you are exploring rehabilitation options for post-stroke recovery, discuss targeted neural interventions with a neurologist. Understanding whether a patient’s dysphagia is linked to brainstem circuit disruption may influence the success of physical or acupuncture-based therapies.

Comparison: Current vs. Emerging Swallowing Therapies

Frequently Asked Questions

  • What is the primary role of the hypoglossal nucleus in swallowing? It acts as a central motor output node that receives signals from brainstem swallowing centers and coordinates muscle activity in the throat and tongue.
  • Is acupuncture at CV23 effective for all stroke patients? The study shows it is effective in mouse models of PSD by restoring muscle electrical activity, but clinical application should be managed by licensed rehabilitation specialists.
  • How does this research differ from previous studies? Previous studies identified that the motor cortex and brainstem were involved, but this research provides the first direct evidence of the monosynaptic link between the CV23 acupoint and the 12N.

Are you interested in the latest breakthroughs in stroke recovery? Subscribe to our newsletter for updates on neural rehabilitation research and clinical advancements.

June 23, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Why Autoimmunity Increases With Age: The Role of Senescent Immune Cells

by Chief Editor June 21, 2026
written by Chief Editor

Immune aging, or immunosenescence, triggers a decline in the body’s ability to fight infections and tumors while simultaneously increasing the risk of chronic inflammation and autoimmune diseases. According to a review published in the Journal of Clinical Investigation, the human immune system reaches a critical inflection point around age 50, where molecular signatures of aging first appear in the spleen and lymph nodes. This biological shift explains why most of the 19 most prevalent autoimmune diseases typically emerge in the second half of life.

Why does the immune system lose efficiency with age?

The immune system faces a constant, heavy demand for new cell production, which drives biological aging. Research cited in the Journal of Clinical Investigation notes that the body generates approximately 70 million naïve B cells and 82 million naïve T cells daily. This massive proliferative burden causes hematopoietic stem cells (HSCs) to develop an age-associated myeloid lineage bias. As these cells replicate, they accumulate mutations that can lead to clonal hematopoiesis of indeterminate potential, a condition where mutated stem cells outcompete healthy ones, often promoting systemic inflammation.

Did you know?
The thymus, the organ responsible for T cell production, undergoes “thymic involution” as we age. This process reduces the diversity of T cells available to fight new pathogens, effectively narrowing the immune system’s defensive repertoire.

How does immune aging trigger autoimmune disease?

Autoimmunity in older adults often stems from the breakdown of internal cellular coordination, particularly within T cells. In conditions like rheumatoid arthritis (RA), CD4+ T cells exhibit impaired mitochondrial health. According to the review, these cells fail to import essential DNA repair machinery into their mitochondria. This leads to mitochondrial DNA (mtDNA) fragments leaking into the cell’s cytosol, where they act as damage-associated molecular patterns (DAMPs) that trigger chronic, body-wide inflammation.

How does immune aging trigger autoimmune disease?
Condition Immune Mechanism
Rheumatoid Arthritis (RA) Accelerated T cell aging; mitochondrial dysfunction and organelle stress.
Giant Cell Arteritis (GCA) Delayed immune aging; stem-like T cells attacking aging vascular tissue.

Is there a difference between RA and GCA aging?

The progression of autoimmunity varies significantly based on how immune cells age. While RA is characterized by “accelerated” immune aging—where T cells become exhausted and dysfunctional—GCA represents a “stalled” or “delayed” aging process. In GCA patients, stem-like CD4+ T cells retain a youthful, proliferative capacity that is otherwise lost in advanced age. These cells infiltrate aging arterial tissue, causing damage because the immune system remains “too young” and aggressive compared to the aged, neoantigen-rich tissue it is attacking.

Pro Tip:
Focusing on metabolic resilience may be the next frontier in medicine. Research suggests that restoring mitochondrial repair mechanisms could potentially “rejuvenate” immune function and improve vaccine responsiveness in older populations.

Frequently Asked Questions

What is the “inflection point” for immune aging?

Research indicates an aging inflection point occurs around age 50, marked by molecular changes in immune organs like the spleen and lymph nodes.

Mayo Clinic Q&A podcast: Aging and the immune system

Can immune aging be reversed?

While current medical science is still in the research phase, experts are exploring therapies to restore metabolic resilience, improve mitochondrial repair, and temper mTOR signaling to preserve immune function.

Why do autoimmune diseases appear later in life?

Most autoimmune diseases are linked to the accumulation of cellular stress, organelle dysfunction, and the loss of immune tolerance that occurs as the body ages, typically becoming clinically overt after age 50.


Are you interested in learning more about how lifestyle factors influence cellular aging? Subscribe to our newsletter for the latest updates on immunology and healthy aging research.

June 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Prunes vs. Supplements: Study Evaluates Impact on Male Bone Density

by Chief Editor June 12, 2026
written by Chief Editor

Daily consumption of prunes does not increase bone mineral density (BMD) in older men more effectively than standard calcium and vitamin D3 supplementation, according to a randomized controlled trial published in the journal Nutrients. While the study found minor shifts in specific bone biomarkers, researchers observed no measurable improvement in bone density over a 12-month period compared to a control group receiving only vitamins.

Why Prunes Were Studied for Bone Health

Researchers targeted prunes because of their high polyphenol content, which has shown promise in animal models for protecting bone tissue. Osteoporosis affects approximately 10 million people in the United States, including two million men, according to study data. Men typically lose between 0.5% and 1% of their bone mass annually after age 60, creating a need for effective, low-risk interventions. Standard pharmacological treatments for bone density often carry side effects like gastrointestinal distress or musculoskeletal pain, prompting investigators to look for nutritional alternatives.

Did you know?
The study excluded men with chronic conditions like diabetes, kidney disease, or cancer to isolate the effects of prunes on otherwise healthy aging bone metabolism.

Study Methodology and Participant Data

The trial enrolled 62 men aged 55 to 80, with 59 completing the full year of the study. Participants were split into three groups: those consuming 50 grams of prunes daily, those consuming 100 grams, and a control group. Every participant, including the control group, received a baseline supplement of 800 IU of vitamin D3 and 450 mg of elemental calcium. Compliance was tracked through self-reported daily logs, and researchers monitored progress using dual-energy X-ray absorptiometry (DXA) scans at three, six, and 12-month intervals.

Study Methodology and Participant Data

What the Biomarkers Revealed

While total and lumbar spine BMD did not change significantly across any group, the researchers noted specific shifts in bone-related proteins. According to the study findings, levels of tartrate-resistant acid phosphatase 5b (TRAP5b)—a marker associated with bone resorption—increased over time in all groups. However, the control group experienced a significantly greater increase in TRAP5b compared to the 100-gram prune group. Despite this, the authors noted these findings are exploratory, as the differences in biomarkers did not translate into detectable changes in bone density.

Comparison of Findings

Metric Result
Lumbar Spine BMD No significant difference between groups
Total BMD No significant change over 12 months
Osteocalcin No significant difference between groups

Limitations and Future Research Directions

The study authors identified several constraints that may have influenced the outcome. The sample size was relatively small, and the study faced disruptions due to the COVID-19 pandemic. Furthermore, the researchers noted that the participants were generally healthy, which may mask the potential benefits of prunes in individuals with more severe bone loss. Because the study lacked a “true” placebo group—meaning everyone received vitamin D3 and calcium—it remains unclear if prunes provide any benefit beyond those standard supplements.

PRUNES are a SUPERFOOD for your BONES!
Pro Tip:
Always consult with a healthcare provider before adding significant amounts of fiber-rich fruit like prunes to your diet, especially if you are managing existing gastrointestinal or metabolic conditions.

Frequently Asked Questions

Can prunes reverse osteoporosis?

No, this study found that daily prune consumption did not improve bone mineral density in older men over a one-year period.

Can prunes reverse osteoporosis?

Do prunes offer any health benefits for men?

The study observed a decrease in resting heart rate in the 50-gram prune group, but researchers did not attribute this directly to the fruit in a clinical sense. Further research is needed to confirm these secondary observations.

Should I stop taking Vitamin D3 if I eat prunes?

No. All participants in this study were provided with vitamin D3 and calcium, as these are established standards for bone health. There is no evidence in this trial to suggest prunes replace these essential nutrients.


Are you interested in learning more about how nutrition impacts aging? Subscribe to our weekly newsletter for the latest updates on clinical nutrition research and bone health strategies.

June 12, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

PSMA PET: Detecting High-Risk Prostate Cancer Bone Metastases

by Chief Editor June 1, 2026
written by Chief Editor

The Invisible Threat: Why Standard Scans Are Failing Prostate Cancer Patients

Imagine receiving a report from your doctor stating that your bone scan is perfectly clear. You breathe a sigh of relief, thinking the cancer is contained. But beneath the surface, a silent progression is already underway. This is the harrowing reality for a significant number of prostate cancer patients relying on conventional imaging.

For decades, CT scans and traditional bone scans have been the frontline tools for staging prostate cancer. However, new research is exposing a dangerous blind spot in these technologies. They often fail to detect micro-metastases—tiny deposits of cancer cells that are too small for standard equipment to see, but large enough to fundamentally alter a patient’s survival outlook.

Recent findings presented at the Society of Nuclear Medicine and Molecular Imaging highlight a staggering gap: over 80% of patients whose PSMA PET scans showed bone lesions actually had “completely normal” results on conventional scans. This discrepancy isn’t just a technicality; it is a matter of life and death.

Did you know? PSMA (Prostate-Specific Membrane Antigen) is a protein that is highly overexpressed on the surface of prostate cancer cells. By using a radioactive tracer that “sticks” to this protein, doctors can light up even the smallest clusters of cancer cells that traditional scans would miss entirely.

The PSMA Revolution: Seeing the Unseen

The shift toward PSMA PET imaging represents a paradigm shift in oncology. Unlike conventional scans that look for structural changes in bone or tissue, PSMA PET is a molecular tool. It looks for the biological signature of the cancer itself.

The implications of this sensitivity are profound. According to recent clinical data, patients who have even one to five bone metastases detected via PSMA PET—despite a “clean” conventional scan—face a much more aggressive disease trajectory. These patients have a five times higher risk of progressing to treatment-resistant cancer and a nearly four times higher risk of death compared to those with no detectable metastases.

This data suggests that the “wait and see” approach, often dictated by standard imaging, may be costing patients precious time. When the imaging says everything is fine, but the molecular reality is different, the window for effective, early intervention begins to close.

Pro Tip: If you are undergoing staging for prostate cancer, ask your oncology team: “Is a PSMA PET scan appropriate for my specific case to ensure we aren’t missing micro-metastases?”

Future Trend 1: The Rise of Theranostics

The most exciting frontier emerging from this research is the concept of Theranostics—a portmanteau of “therapy” and “diagnostics.” We are moving toward a future where the same tool used to find the cancer is used to kill it.

Once a PSMA PET scan identifies exactly where the cancer cells are located, clinicians can use “targeted radioligand therapy.” This involves attaching a therapeutic radioactive isotope to the same PSMA-seeking molecule. The molecule travels through the bloodstream, finds the cancer cells, and delivers a localized dose of radiation directly to the tumor, sparing much of the healthy surrounding tissue.

This “seek and destroy” mission marks the end of the “one-size-fits-all” chemotherapy era and the beginning of hyper-personalized cancer care.

Future Trend 2: AI-Enhanced Radiomics

As imaging becomes more complex, the human eye—even that of a highly trained radiologist—can only go so far. The next wave of innovation involves Artificial Intelligence (AI) and Machine Learning integrated into PET imaging.

Finding Early-Stage Prostate Cancer with a PSMA PET Scan

Future diagnostic suites will likely use AI to perform “radiomic” analysis. This involves the computer analyzing thousands of tiny features within an image that are invisible to humans. AI could potentially predict the aggressiveness of a tumor or its likelihood of spreading before a single lesion even becomes visible, allowing for even earlier preventative measures.

Future Trend 3: Shifting Treatment Protocols

The data is clear: when PSMA PET finds something, the treatment must change. We are seeing a trend toward intensified early intervention. Rather than waiting for biochemical recurrence (an increase in PSA levels) or physical symptoms, oncologists are beginning to use PSMA PET results to justify more aggressive initial treatments.

This might include early hormone therapy, advanced radiation protocols, or even surgical interventions that would have previously been deemed “unnecessary” based on a faulty, conventional bone scan. The goal is to treat the biological reality of the disease, not just the visual evidence on a CT scan.

For more insights into the evolving landscape of cancer care, explore our latest coverage on advancements in oncology.

Frequently Asked Questions

Q: What is the main difference between a bone scan and a PSMA PET scan?
A: A bone scan looks for structural changes or damage to the bone itself, which often only happens after cancer has already caused significant damage. A PSMA PET scan looks for the specific protein on the cancer cells, allowing it to detect the cancer much earlier, often before the bone is even damaged.

Q: Does a “normal” bone scan mean my cancer hasn’t spread?
A: Not necessarily. As recent studies show, conventional scans can miss small deposits of cancer. A PSMA PET scan provides a much more accurate picture of whether the cancer has spread to the bones.

Q: Is PSMA PET imaging widely available?
A: It is increasingly available at major academic cancer centers and specialized imaging facilities. You should consult your oncologist to see if it is covered by your insurance and appropriate for your staging.

Q: How does detecting bone metastases early change my treatment?
A: Early detection allows doctors to implement more aggressive or targeted therapies sooner, which can help prevent the cancer from becoming treatment-resistant and can significantly improve long-term survival rates.

Stay Ahead of the Curve in Medical Innovation

The world of oncology is changing faster than ever. Don’t miss out on the latest breakthroughs and expert analysis.

Join our newsletter to receive weekly updates on the future of healthcare delivered straight to your inbox.

Subscribe Now

Or, leave a comment below: How do you think AI will change your healthcare experience?

June 1, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Calcium and vitamin D supplements show limited fracture prevention benefits

by Chief Editor May 21, 2026
written by Chief Editor

Beyond the Supplement Bottle: The Future of Bone Health and Fall Prevention

For decades, the standard advice for aging adults has been simple: take calcium and vitamin D to keep your bones strong and avoid fractures. It became a routine part of healthcare, with prescriptions and over-the-counter sales climbing steadily. However, a seismic shift is occurring in how we approach geriatric wellness.

Recent evidence published in The BMJ has challenged the long-held belief that routine supplementation is the key to preventing falls and fractures. After reviewing 69 randomised controlled trials involving 153,902 adults, researchers found that calcium, vitamin D, or a combination of both offered little to no clinically meaningful benefit for the majority of older people.

Did you know? Almost a third of people aged 65 and older experience a fall each year. These events often lead to fractures that can significantly reduce quality of life and increase the need for residential care.

The Shift Toward Functional Movement

As the limitations of supplements become clearer, the medical community is pivoting toward “functional” prevention. The data suggests that the future of bone health isn’t found in a pill, but in movement. Rather than focusing on the chemical composition of the bone, the trend is moving toward the stability of the body.

The Shift Toward Functional Movement
Bone

We are seeing a redirected focus toward interventions that have a proven track record of success, specifically:

  • Resistance Exercise: Weight-bearing activities that challenge the muscles and bones.
  • Balance Training: Targeted exercises designed to reduce the likelihood of a fall occurring in the first place.
  • Combined Modalities: Programs that integrate physical activity with education and hazard assessment.

The goal is moving from “bone density” to “fall resilience.” It is one thing to have strong bones; it is another to have the balance and strength to ensure those bones never hit the ground.

Pro Tip: The “Safe Home” Audit

Prevention starts with your environment. Conduct a “hazard assessment” of your living space. Remove loose rugs, improve lighting in hallways, and install grab bars in bathrooms. These simple environmental changes often provide more immediate protection than a daily supplement.

Personalized Medicine vs. Routine Supplementation

One of the most critical takeaways from the BMJ review is that “routine” supplementation—giving the same advice to everyone—is likely ineffective. The researchers noted that their findings may not apply to individuals with specific bone disorders or those already receiving drug treatments for osteoporosis.

View this post on Instagram about Personalized Medicine, Routine Supplementation One
From Instagram — related to Personalized Medicine, Routine Supplementation One

The future of bone health is precision medicine. Instead of a blanket recommendation, we are moving toward a model where supplementation is targeted based on:

  • Specific medical diagnoses (such as severe osteoporosis).
  • Individual deficiency levels confirmed by clinical testing.
  • Interaction with existing pharmaceutical treatments.

This approach ensures that those who truly need these nutrients receive them, while the general population avoids unnecessary supplements that provide no meaningful benefit.

The Impact on Clinical Guidelines and Public Health

The discrepancy between current guidelines and recent evidence is stark. Despite a lack of consistent results in previous reviews, many regulatory agencies and clinicians continue to recommend vitamin D and calcium. This creates a “guideline gap” that is now being addressed.

The call to action for guideline panels is clear: re-evaluate general recommendations. We can expect a transition where public health funding is redirected from supplement promotion toward community-based exercise programs and tailored risk assessments.

By shifting the focus from the pharmacy to the gym and the home, healthcare systems can better address the global public health priority of reducing fracture-related injuries.

Expert Insight: The evidence from 36 trials involving 92,045 participants showed high certainty that vitamin D supplements alone had little to no effect on preventing fractures. When combined with calcium (across 15 trials and 51,126 participants), the result remained the same. This suggests that the synergy we once hoped for between these two nutrients may not translate into actual fracture prevention for the average older adult.

Common Questions About Bone Health and Supplements

Do I need to stop taking my calcium or vitamin D supplements?

You should never stop a prescribed medication or supplement without consulting your doctor. While routine supplementation may not prevent falls for most people, those with specific bone disorders or those on osteoporosis medication may still require them.

Common Questions About Bone Health and Supplements
Vitamin supplements

What is the best way to prevent fractures in older age?

The most effective strategies currently include a combination of balance and resistance exercises, along with home safety assessments to remove fall hazards.

Are there any benefits to calcium and vitamin D at all?

These nutrients are essential for the body, but the recent focus is on whether supplementing them beyond a healthy diet actually prevents the specific outcomes of falls and fractures in the general older population.

Why are supplements still recommended if the evidence is unclear?

Medical guidelines often take time to update. However, researchers are now urging regulatory agencies to align their recommendations with the latest high-certainty evidence.

What are your thoughts on the shift from supplements to exercise for bone health? Have you noticed a change in the advice you receive from your healthcare provider? Let us know in the comments below or subscribe to our newsletter for more evidence-based health updates.

May 21, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Maternal antibodies provide lifelong protection against adult gum disease

by Chief Editor April 29, 2026
written by Chief Editor

The Hidden Legacy of Motherhood: How Prenatal Immunity Shapes Lifelong Oral Health

A mother’s influence extends far beyond genetics and nurturing; it appears to lay the very foundation for her child’s oral health, protecting against gum disease decades later. New research from the Hebrew University of Jerusalem reveals that maternal antibodies, transferred both in utero and through breastfeeding, actively “program” a child’s immune system to fight off oral diseases, including periodontitis.

View this post on Instagram about The Hidden Legacy of Motherhood, Hebrew University of Jerusalem
From Instagram — related to The Hidden Legacy of Motherhood, Hebrew University of Jerusalem

The Two Pathways of Maternal Immunity

The study, published in Nature Communications, highlights two distinct pathways through which mothers provide this crucial immune support. The first, and arguably most impactful, involves the transfer of IgG antibodies during pregnancy. These antibodies travel to the newborn’s salivary glands, where they are secreted into saliva, essentially training the immune system to distinguish between harmless bacteria and potential threats.

Prof. Avi-Hai Hovav and DMD/PhD student Reem Naamneh, who led the research at the Faculty of Dental Medicine at Hebrew University, discovered that offspring lacking these prenatal antibodies exhibited a hyper-activated immune response and increased bacterial loads in their gums. This early immune misstep translated to a significantly higher susceptibility to periodontitis in adulthood – a condition marked by inflammation and bone loss around the teeth.

Beyond Initial Protection: Breastfeeding’s Role in Oral Barrier Development

While prenatal antibodies establish the immune “tone,” antibodies delivered through breast milk play a different, yet equally vital, role. The research demonstrates that postnatal antibodies are essential for the proper maturation of the oral epithelium – the protective lining of the mouth. These antibodies regulate the timing of “barrier sealing,” ensuring the mouth’s defenses are fully formed at the appropriate moment.

Beyond Initial Protection: Breastfeeding’s Role in Oral Barrier Development
Breastfeeding Pasteurellaceae Oral Barrier Development While

Disrupting this process, for example, with antibiotics, compromises the integrity of the oral barrier, leaving it vulnerable to infection. This highlights the delicate interplay between the microbial environment and the development of a robust oral defense system.

Targeting Specific Pathogens: Pasteurellaceae and Gum Disease

The team’s investigation pinpointed specific oral pathogens targeted by maternal IgG antibodies. They found that these antibodies recognize and bind to members of the Pasteurellaceae family, bacteria known to contribute to aggressive forms of gum disease. This discovery is a significant step towards understanding the origins of oral diseases and identifying potential intervention points.

Why Are Maternal Antibodies Vital For Newborn Flu Protection? – Influenza Relief Guide

The Future of Preventive Dentistry: Maternal Immunization?

The findings open exciting possibilities for preventive strategies. Researchers suggest that vaccinating mothers during pregnancy could enhance the transfer of specific antibodies to their children, effectively pre-programming their immune systems to resist chronic oral infections. This proactive approach could dramatically reduce the incidence of periodontitis and other oral health issues in future generations.

Did you know? The foundations of a healthy adult smile are being laid even before a baby’s first tooth emerges.

The Expanding Landscape of Maternal Immunity Research

This research builds upon a growing body of evidence demonstrating the profound and lasting impact of maternal immunity on various aspects of a child’s health. Studies have shown links between maternal antibodies and protection against allergies, autoimmune diseases, and even certain cancers. The oral microbiome, and its connection to systemic health, is increasingly recognized as a critical area for investigation.

The Expanding Landscape of Maternal Immunity Research
Immunity Breastfeeding

Pro Tip: Maintaining excellent oral hygiene during pregnancy is crucial, not only for the mother’s health but also for establishing a healthy oral microbiome for the developing child.

FAQ

Q: How long does maternal antibody protection last?
A: The study suggests lifelong protection against adult gum disease, though the duration and effectiveness can vary.

Q: Can breastfeeding compensate for a lack of prenatal antibodies?
A: Breastfeeding provides essential antibodies for oral barrier development, but it doesn’t fully replicate the immune “programming” effect of prenatal IgG transfer.

Q: Is maternal immunization currently available?
A: Maternal immunization for oral health is still in the research phase, but the findings suggest it’s a promising avenue for future preventive strategies.

Q: What is periodontitis?
A: Periodontitis is a serious gum infection that damages the soft tissue and bone that support teeth. It can lead to tooth loss.

This research underscores the remarkable power of maternal immunity and its lasting impact on a child’s health. As we continue to unravel the complexities of the oral microbiome and the immune system, we move closer to a future where preventive strategies can ensure a lifetime of healthy smiles.

Want to learn more about oral health? Explore our articles on gum disease prevention and the oral microbiome.

April 29, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Researchers uncover new mechanism linking metabolism, immunity, and skeletal health

by Chief Editor April 25, 2026
written by Chief Editor

Rethinking the “Heavy Bone” Myth: The Hidden Cost of Obesity

For years, a common belief in skeletal biology was that higher body weight actually benefited bone health. The logic was simple: increased mechanical loading from extra weight should, in theory, strengthen the skeleton. However, groundbreaking research is now flipping this narrative on its head.

We now realize that obesity doesn’t just put physical pressure on joints; it fundamentally reshapes the internal environment of the bone marrow. This shift transforms the marrow from a supportive niche into a driver of bone degradation, challenging everything we thought we knew about the relationship between weight and skeletal integrity.

Did you know? Bone marrow adipose tissue (BMAT) is not just passive fat storage. It is an active endocrine organ that can secrete signaling molecules to regulate both your immune system and your bone density.

The Biological Trigger: How Bone Marrow Fat Destroys Bone

The mechanism behind this bone loss is a complex chain reaction. In obese conditions, bone marrow adipocytes (fat cells) expand rapidly. These expanded cells increase the production of a signaling molecule called MCP-1.

View this post on Instagram about Bone, Future
From Instagram — related to Bone, Future

MCP-1 acts as a beacon, recruiting myeloid immune cells and steering them toward an immunosuppressive state. These cells begin expressing PD-L1 (programmed death-ligand 1). Even as these PD-L1+ cells suppress T-cell activity—potentially explaining why obesity is linked to reduced vaccine effectiveness and higher infection risks—they do something far more damaging to the skeleton.

These PD-L1-expressing cells interact with PD-1 receptors on osteoclast precursors. This specific interaction promotes the differentiation of these precursors into mature osteoclasts—the specialized cells responsible for resorbing and degrading mineralized bone matrix. The result is a significant loss of both trabecular and cortical bone volume.

For more on how metabolic health affects the body, witness our guide on metabolic health and systemic inflammation.

Future Therapeutic Trends: Repurposing Cancer Drugs for Bone Health

One of the most exciting prospects arising from this research is the potential to repurpose existing medical technology. The PD-1/PD-L1 axis is already a primary target in cancer immunotherapy. This suggests a future where immune checkpoint inhibitors could be adapted to treat obesity-related bone disorders.

Targeting the JNK Pathway

Recent data indicates that PD-1/PD-L1 inhibitors can exert direct effects on bone metabolism. By inhibiting the JNK pathway, these agents may reduce the proliferation and resorptive capacity of osteoclasts, effectively slowing down bone loss.

Pharmacological Blockade

Research has shown that blocking the PD-1/PD-L1 signaling axis during the early stages of osteoclast precursor development can mitigate bone resorption. This opens the door for targeted pharmacological interventions that preserve bone integrity without needing to address total body weight first.

Pharmacological Blockade
Bone Future Health
Pro Tip: Future treatment for obesity-related osteoporosis may require a multidisciplinary approach, combining the expertise of endocrinologists, immunologists, and bone specialists to manage the intersection of metabolism and immunity.

The Broader Impact: Immunity and Skeletal Health

The discovery of this link suggests that the skeleton is far more integrated with the immune system than previously realized. The expansion of bone marrow fat creates an “immunosuppressive microenvironment” that disrupts the delicate immune equilibrium.

This suggests that treating bone loss in obese patients isn’t just about calcium or vitamin D; it’s about managing the immune checkpoint pathways. By reducing bone marrow adipogenesis—as seen in studies using BMAd-Pparg KO models—researchers have successfully reduced the number of PD-L1+ myeloid cells and improved bone structure.

Check out our related article on how immune checkpoints regulate the body to learn more about PD-L1.

Frequently Asked Questions

What is the role of MCP-1 in bone loss?

MCP-1 is a chemokine secreted by expanded bone marrow fat in obese individuals. It recruits myeloid immune cells and promotes their expression of PD-L1, which eventually drives the formation of bone-resorbing osteoclasts.

Frequently Asked Questions
Bone Future

Can PD-1/PD-L1 inhibitors actually help bones?

Yes, evidence suggests that blocking this pathway can reduce osteoclast proliferation and resorptive activity, potentially protecting bone volume in the context of obesity.

Why does obesity lead to weaker bones if weight usually strengthens them?

While mechanical loading is beneficial, the metabolic changes caused by obesity—specifically the expansion of bone marrow fat—trigger an immune response that accelerates bone resorption, outweighing the benefits of the extra weight.

Does bone marrow fat affect the rest of the immune system?

Yes. The PD-L1+ myeloid cells recruited by bone marrow fat suppress T-cell activity, which may contribute to impaired immune responses, such as decreased vaccine effectiveness.

Join the Conversation

Do you think immune-based therapies will turn into the new standard for treating osteoporosis? Let us know your thoughts in the comments below or subscribe to our newsletter for the latest breakthroughs in metabolic medicine!

April 25, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

Long-term study supports tenofovir alafenamide for chronic hepatitis B

by Chief Editor April 24, 2026
written by Chief Editor

The Shift Toward Long-Term Safety in Hepatitis B Care

For years, managing chronic hepatitis B (CHB) has been a balancing act between suppressing the virus and managing the side effects of medication. Recent long-term data is now highlighting a significant trend: the transition toward treatments that prioritize not just viral suppression, but the preservation of organ health over decades.

The focus is increasingly shifting toward Tenofovir alafenamide (TAF), a nucleoside reverse transcriptase inhibitor (NRTI) designed to decrease the amount of hepatitis B virus (HBV) in the blood. While earlier treatments were effective, the long-term impact on bone and kidney health has become a primary concern for clinicians, especially as the patient population ages.

Did you recognize? TAF belongs to a class of medications called NRTIs. While these drugs are highly effective at reducing the viral load in the blood, they are not a cure for hepatitis B and may not prevent the spread of the virus to others.

Prioritizing Bone and Kidney Health

One of the most critical trends in HBV therapy is the move away from medications that cause gradual decline in renal function and bone density. In a comprehensive eight-year analysis of Chinese participants, TAF demonstrated a superior safety profile compared to tenofovir disoproxil fumarate (TDF).

Prioritizing Bone and Kidney Health
Tenofovir Prioritizing Bone and Kidney Health One The Impact of Switching Treatments

Data shows that in patients taking TAF, the estimated glomerular filtration rate (eGFR)—a key measure of kidney function—and bone mineral density in the hip and spine remained stable over the eight-year period. What we have is a vital development for aging populations who are already at a higher risk for osteoporosis and kidney dysfunction.

The Impact of Switching Treatments: Reversibility and Recovery

A pivotal discovery in recent research is the potential for recovery when switching from TDF to TAF. For patients who experienced small declines in renal and bone parameters during TDF treatment, these markers showed improvement after switching to an open-label TAF regimen.

View this post on Instagram about The Impact of Switching Treatments, Reversibility and Recovery
From Instagram — related to The Impact of Switching Treatments, Reversibility and Recovery

This suggests a future where “treatment switching” becomes a standard protocol to mitigate long-term toxicity. By transitioning patients to TAF, healthcare providers can maintain high rates of viral suppression while actively improving the patient’s overall physiological health.

Pro Tip: Consistency is key. Because stopping TAF can cause the HBV condition to suddenly worsen, it is essential to take the medication exactly as directed, typically once daily with food, and to never miss a dose.

Understanding Viral Suppression and Resistance

The effectiveness of TAF remains robust over the long term. In studies excluding missing data, viral suppression rates (HBV DNA < 29 IU/mL) reached 95.2% for those on a consistent TAF regimen and 95.5% for those who switched from TDF to TAF at the eight-year mark.

#2 – One Year Outcome of Bictegravir/Emtricitabine/Tenofovir Alafenamide (…) – Carina A. Rodriguez

Perhaps most importantly for the future of HBV treatment, no resistance to TAF was detected during these long-term observations. This lack of resistance, combined with high alanine aminotransferase normalization rates, reinforces TAF’s position as a preferred long-term option for maintaining liver health.

For more information on drug classifications, you can explore resources like MedlinePlus to understand how NRTIs function.

Frequently Asked Questions

Does TAF cure hepatitis B?
No, Tenofovir alafenamide (TAF) does not cure hepatitis B, though it is used to treat the chronic infection by decreasing the amount of HBV in the blood.

What is the typical dose for adult patients with compensated liver disease?
TAF is indicated for adult patients with chronic HBV infection and compensated liver disease at an oral dose of 25 mg taken once daily.

Can I stop taking TAF if I experience better?
No. You should continue taking TAF even if you feel well. Stopping the medication can cause your condition to worsen suddenly, and doctors typically order regular lab tests for several months after any cessation of treatment.

Is TAF safer for the kidneys than TDF?
Yes, evidence suggests TAF has improved renal and bone safety compared to TDF, with stable eGFR and bone mineral density observed over long-term use.

What are your thoughts on the evolution of HBV treatments? Have you or a loved one experienced the transition between different antiviral therapies? Share your experiences in the comments below or subscribe to our newsletter for the latest updates in hepatology.

April 24, 2026 0 comments
0 FacebookTwitterPinterestEmail
Health

BMI increases in early childhood may reflect muscle growth, not fat

by Chief Editor April 16, 2026
written by Chief Editor

Rethinking Childhood Obesity: Why BMI Alone Isn’t Enough

For decades, the body mass index (BMI) has been a primary tool in assessing weight status and identifying potential obesity risks in children. But, a growing body of research, including a new study published in The Journal of Nutrition, suggests that relying solely on BMI can be misleading. The study, analyzing data from over 2,400 children and adolescents in the U.S., reveals a disconnect between BMI and a more accurate measure of body fat: waist-to-height ratio (WHtR).

View this post on Instagram about Obesity, Nutrition
From Instagram — related to Obesity, Nutrition

The BMI Puzzle: Lean Tissue vs. Fat

BMI, calculated from height and weight, doesn’t differentiate between muscle and fat mass. This is particularly problematic in children, whose bodies are undergoing rapid changes in composition. The new research highlights that the typical “adiposity rebound” – the point around age 6 when BMI starts to rise after an initial decline – may not signify an increase in body fat. Instead, it could reflect healthy growth in lean tissues like muscle and bone.

Researchers found that while BMI followed the expected pattern, WHtR continued to decrease during the same period. This suggests that the BMI increase is not necessarily indicative of increased adiposity. This finding challenges the long-held belief that an early adiposity rebound automatically signals a higher risk of future obesity.

Waist-to-Height Ratio: A More Precise Indicator

WHtR, which compares waist circumference to height, provides a more accurate assessment of abdominal fat – a key indicator of metabolic health risks like heart disease, type 2 diabetes, and high blood pressure. Because it’s less influenced by muscle mass, WHtR offers a clearer picture of a child’s body composition.

The study describes this phenomenon as a “body composition reset,” where the BMI increase coincides with a continued decrease in WHtR, indicating a shift towards healthy lean tissue development. This supports the idea that focusing solely on BMI can lead to misclassifying normal growth patterns as obesity risk.

Global Shift Towards WHtR and the Future of Pediatric Obesity Assessment

The findings align with recent global consensus statements advocating for a more comprehensive approach to obesity diagnosis. Experts now recommend using WHtR, alongside BMI, to confirm obesity diagnoses, particularly in children. Andrew Agbaje, lead author of the study, emphasizes that “obesity should not be diagnosed with BMI alone but confirmed with non-invasive measures such as waist-to-height ratio.”

U of M experts weigh in on changes in childhood BMI growth

This shift in perspective has significant implications for clinical practice. Healthcare providers may need to reconsider how they interpret BMI data in children and incorporate WHtR as a routine screening tool. This could aid avoid unnecessary interventions based on inaccurate assessments.

Did you know? Andrew Agbaje was recently awarded the inaugural American Society for Nutrition Foundation-Novo Nordisk Foundation Flemming Quaade Award for Innovative Approaches to Childhood Obesity, recognizing his contributions to this evolving field.

Beyond WHtR: Emerging Technologies and Personalized Approaches

While WHtR represents a significant improvement over BMI, research continues to explore even more precise methods for assessing body composition. Technologies like bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DEXA) can provide detailed measurements of body fat, muscle mass, and bone density. However, these methods are often more expensive and less accessible than WHtR.

Beyond WHtR: Emerging Technologies and Personalized Approaches
Obesity Childhood Approaches

The future of pediatric obesity assessment likely lies in personalized approaches that combine multiple data points, including WHtR, genetic information, lifestyle factors, and metabolic markers. This will allow healthcare providers to tailor interventions to each child’s unique needs and risk factors.

FAQ

Q: What is adiposity rebound?
A: Adiposity rebound is the point in childhood, typically around age 6, when BMI starts to rise again after an initial decline.

Q: Why is BMI not always accurate?
A: BMI doesn’t distinguish between fat mass and lean tissue, which can be misleading in children whose bodies are rapidly changing.

Q: What is waist-to-height ratio (WHtR)?
A: WHtR is a measure of abdominal fat calculated by dividing waist circumference by height. It’s a more accurate indicator of body fat than BMI.

Q: Should parents be concerned if their child experiences an early adiposity rebound?
A: Not necessarily. The new research suggests that an early rebound doesn’t automatically mean a child is at risk for obesity. It’s important to consider other factors, such as WHtR and overall health.

Pro Tip: Focus on promoting healthy habits – a balanced diet, regular physical activity, and adequate sleep – rather than solely fixating on weight or BMI.

Want to learn more about childhood nutrition and healthy weight management? Explore resources from the American Society for Nutrition.

April 16, 2026 0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts

Recent Posts

  • PASTEF Prioritizes Political Gimmicks Over Public Policy

    July 12, 2026
  • Interview with MeteoSwiss Director Stefan Uhlenbrook

    July 12, 2026
  • At Least 27 Dead in Bangkok Fire

    July 12, 2026
  • Dario Barassi’s Dream Family Holiday Album: ‘Ibiza, You’re Winning Us Over

    July 12, 2026
  • Watch: Céline Dept vs. iShowSpeed in the Creator Cup Live

    July 12, 2026

Popular Posts

  • 1

    Maya Jama flaunts her taut midriff in a white crop top and denim jeans during holiday as she shares New York pub crawl story

    April 5, 2025
  • 2

    Saar-Unternehmen hoffen auf tiefgreifende Reformen

    March 26, 2025
  • 3

    Marta Daddato: vita e racconti tra YouTube e podcast

    April 7, 2025
  • 4

    Unlocking Success: Why the FPÖ Could Outperform Projections and Transform Austria’s Political Landscape

    April 26, 2025
  • 5

    Mecimapro Apologizes for DAY6 Concert Chaos: Understanding the Controversy

    May 6, 2025

Follow Me

Follow Me
  • Cookie Policy
  • CORRECTIONS POLICY
  • PRIVACY POLICY
  • TERMS OF SERVICE

© 2026 Newsy Today. All rights reserved.
For contact, advertising, copyright, issues email: [email protected]


Back To Top

For contact, advertising, copyright, issues email: [email protected]

Newsy Today
  • Business
  • Entertainment
  • Health
  • News
  • Sport
  • Tech
  • World